Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Drug: Dose escalation Sponsors:   University of Liverpool;   European and Developing Countries Clinical Trials Partnership (EDCTP);   Joint Clinical Research Centre, Kampala, Uganda;   University of Cape Town, Cape Town, South Africa;   Infectious Diseases Institute, Makerere University College of Health Scienc es, Kampala, Uganda;   University of Turin, Turin, Italy Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

In conclusion, the author of this paper mentioned that immunization gap needs to be handle systematically. Immunization data released on 2017 showed that complete immunization was given only to 20% of targeted group, while almost 75% were either unvaccinated or unknown. During the outbreak of diphteria in Indonesia, the WHO also reported several countries with similar problem such as Bangladesh, Haiti and Yamen. It was shown that a coordination between doctors in clinic/hospital with public health officer to conduct an epidemiological investigation, in conjunction with giving prophylaxis and assuring the logistics of anti-...
Source: Acta medica Indonesiana - Category: Internal Medicine Tags: Acta Med Indones Source Type: research
CONCLUSION: Through the study, it was possible to find that the location of border cities can be determinant for a negative outcome. PMID: 31691724 [PubMed - in process]
Source: Revista gaucha de enfermagem EENFUFRGS - Category: Nursing Tags: Rev Gaucha Enferm Source Type: research
Objectives: Drug–drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated dose of RAL when administered with RIF to HIV and TB co-infected children. Design: P1101 is a phase I/II open-label dose-finding study of RAL with RIF for children 2 to less than 12 years of age beginning treatment for HIV and active TB. Setting: Four sites in South Africa. Methods: Chewable RAL was given at 12 m...
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Tuberculosis (TB) ranks second, next to AIDS making it most formidable disease if the present age. One of the crucial enzymes involved in cell wall synthesis of Mycobacterium tuberculosis, InhA (enoyl acyl carrier protein reductase) has been authenticated as an effective target for anti-mycobacterial drug development. In the current work, we have developed novel derivatives of 1,2,4-triazole-5-thione as promising InhA inhibitors. We rationally designed these 1,2,4-triazole-5-thione compounds, synthesized and spectrally characterized them. Anti-mycobacterial potential was determined by resazurin microtiter assay using Mtb H...
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
Notice from the Centers for Disease Control and Prevention extending the comment period for an earlier notice making revisions to an information collection related to the Resources and Services Database of the CDC National Prevention Information Network (NPIN). NPIN serves as the reference and referral service for information on HIV/AIDS, hepatitis, sexually transmitted diseases, and tuberculosis. Comments are due by within 30 days of this notice.
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
In a landmark development, global biopharmaceutical company Sanofi will lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, an official release said on Thursday.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
Condition:   Tuberculous Meningitis Interventions:   Drug: Aspirin;   Drug: Placebo of aspirin;   Drug: WHO TBM treatment;   Drug: Intensified TBM treatment Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   European Union;   European and Developing Countries Clinical Trials Partnership (EDCTP) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conclusions: Even though the mortality rates of all HIV and TB co-infection types have decreased recently, the overall trends in both incidence and prevalence rates of HIV-infected DS-TB and XDR-TB have been increasing since 1990. Efforts to control co-infection across drug resistance types should be continued and further strengthened. PMID: 31656655 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
ConclusionsThis study confirmed that massive ACF was not effective in general population in a moderate TB prevalence setting. The priority should be the definition and targeting of high-risk groups in the community before the screening process is launched. The shorter time interval of ACF between TB symptoms onset and linkage to healthcare service may decrease the risk of TB community transmission. Furthermore, integrated ACF strategy in the National Project of Basic Public Health Service may have long term public health impact.
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research
[Premium Times] The Nigerian government has pledged to release $12 million to end epidemics of HIV/AIDS, tuberculosis, malaria and other preventable and treatable disease across the globe.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news
More News: African Health | Clinical Trials | HIV AIDS | Infectious Diseases | Italy Health | Partnerships | Research | Study | Tuberculosis | Uganda Health